Six out of every 10 respondents to a MedPage Today poll said the FDA should have been tougher when it ordered that a myocardial infarction warning be added to the black box warning for heart failure on the rosiglitazone (Avandia) label.
Survey Report: FDA Should Have Been Tougher on AvandiaCourtesy MedPage Today Surveys Mon, 11/26/2007 - 16:08
Six out of every 10 respondents to a MedPage Today poll said the FDA should have been tougher when it ordered that a myocardial infarction warning be added to the black box warning for heart failure on the rosiglitazone (Avandia) label. More related itemsVentricular Assist Devices Modestly Increase Survival...
AHA: Biomarker Beats BNP for Heart Failure Mortality...
Child Abuse Is Widely Under-Reported
GoFit Ultimate Burst Resistant Core Stability Ball...
|
Popular by tags Week |
Post new comment